EGFR and cancer: Similarly, homozygous loss of PTEN, which normally acts to dephosphorylate PIP3 and suppress this signaling pathway, has also been identified as a mechanism of EGFR inhibitor resistance in vitro in lung and other cancers.45, 46 However, the clinical significance of these mutations with regard to inhibitor sensitivity remains controversial.